Evidence map›Paper›PMID 41008653›Full record

ReviewBiomolecules2025

MYC and Metabolomics: Can We Use What We Know for DLBCL Subtyping and Diagnosis?

Adrian Florentin Suman, Davide De Luca, Melania Gaggini, Francesco Cucco

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Adrian Florentin SumanInstitute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.ORCID 0009-0000-7318-7361
Davide De LucaInstitute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.ORCID 0009-0008-8701-5147
Melania GagginiInstitute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.ORCID 0000-0002-6311-502X
Francesco CuccoInstitute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.ORCID 0000-0002-7907-1658

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a molecular and clinical heterogenous entity, and, over the past 30 years, many efforts have been made in trying to dissect this diverseness and identify biomarkers capable of efficiently stratifying DLBCL patients and spotting the ones showing a worse clinical outcome. Despite the achievement in this research field, only a few biomarkers have been validated and introduced in a clinical setting. Among those, approximately 5-15% of DLBCL cases harbor

Indexed as

Lymphoma, Large B-Cell, DiffuseMetabolomicsProto-Oncogene Proteins c-mycAmino AcidsBiomarkers, TumorHumansPrognosisAmino AcidsBiomarkers, TumorMYC protein, humanProto-Oncogene Proteins c-mycamino acidsbiomarkersdiagnosislymphomametabolomicsMYC

Identifiers

PMID41008653
PMCPMC12467185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.